Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s decision to grant Pfizer’s Sutent a broad renal cell carcinoma claim suggests a consensus among reviewers that partial responses may be predictive of clinical benefit in RCC.